Insider buying last 90 days
No open-market insider purchases were filed for EHC in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Encompass Health reached a fresh 52-week high this week, with shares up 9.52% over one week amid continued momentum. The company announced the indefinite closure of Sea Pines Rehabilitation Hospital in Melbourne, Florida, following flood damage from torrential rains on 1-2 November 2026, with all patients evacuated safely and employees accounted for. Separately, analysts covering the stock have maintained an average "Buy" recommendation, and a Form 8-K filing was disclosed on 6 November as standard regulatory reporting.
EHC closed at $141.15, up 2.6%, sitting above both its 50-day average of $125.06 and 200-day average of $111.21, with the shorter average above the longer one. The stock trades near its 52-week high of $143.36, well above its 52-week low of $92.77. The GekkoIndex reading of 45.5 places it in the Neutral zone. Price stands 17.8% above the Gekko Fair Value of $119.87.
The next earnings report is scheduled for 4 February 2027, 86 days out and beyond a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears in their respective windows, and one trailblazer holder is noted among institutional categories. Nine covering firms currently rate the stock Buy, with a consensus target of $156.08. Seasonality over the past 5 years shows the next 20 trading days from this point averaging -0.5%, with gains in 3 of those years, a pattern worth noting given the stock's recent strength into a 52-week high.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Encompass Health scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
Above 50 and 200-day
Close $140.99 is above the 50-day ($126.67) and 200-day ($112.14) averages, and the 50-day is above the 200-day.
See the chart49, Neutral
Reading 49 is in the Neutral zone.
See the GekkoIndex14.7% above
Price is 14.7% above Gekko Fair Value (more than 5% above).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 81 days
Next report Feb 4, 2027, 81 days away — outside a typical 20-trading-day hold.
See earnings−0.2% on average
From this point in the calendar, the next 20 trading days averaged −0.2% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Encompass Health closed at $140.99 on Nov 13, 2026, +22.8% over the past year, inside a 52-week range of $92.77 to $143.90.
Use the left and right arrow keys to read daily values.
Put EHC on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Encompass Health treats patients recovering from major medical events, working with them either inside its own facilities or at their place of residence. It has built recognition for guiding recovery from conditions like stroke, neurological disease, heart and lung ailments, brain and spinal injuries, difficult orthopedic cases, and limb loss, with programs structured for both overnight stays and outpatient visits.
Its business splits into two branches. One centers on rehabilitation for patients needing intensive, supervised recovery after a serious diagnosis. The other, focused mainly on the Southeast and Texas, brings Medicare-certified home health offerings to adult patients, covering skilled nursing, social work support, aide services, and physical, occupational, and speech therapy, plus hospice care that comforts dying patients and their loved ones in a home setting.
The company got its start in 1983 and keeps its headquarters in Birmingham, Alabama. It once operated under the name HealthSouth Corporation, adopting the Encompass Health identity in January 2018. Its stock trades on the NYSE under the ticker EHC.
Encompass Health’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 49, in the Neutral zone, up 3.4 points over five sessions.
Up 3.4 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 40 | +0.6% | +5.6% | ||
| Accumulation | 133 | +1.0% | +3.3% | ||
| Neutral (current zone) | 487 | +0.6% | +1.3% | ||
| Distribution | 41 | −1.4% | +0.5% | ||
| Selling | 1 | Too few readings yet | |||
Average EHC share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Encompass Health trades 14.7% above Gekko Fair Value of $122.89, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Encompass Health shares are worth, recalculated every trading day.
$122.89
Gekko Fair Value, Nov 14, 2026
14.7% Overvalued
At the end of Aug 2026 the price was 27.9% above the estimate.
No open-market insider purchases were filed for Encompass Health, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for EHC in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in EHC were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Encompass Health has been buying back its own shares.
From company filings.
1of the funds Gekko tracks holds EHC.
Encompass Health reports on Feb 4, 2027 (81 days away), and beat the EPS estimate in 8 of its last 8 reports.
Feb 4, 2027
81 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Apr 30, 2026 | $1.60 est $1.49 | $1.59B est $1.57B | +4.7% |
| Feb 5, 2026 | $1.46 est $1.30 | $1.54B est $1.54B | +10.2% |
| Oct 29, 2025 | $1.23 est $1.19 | $1.48B est $1.54B | −7.5% |
| Aug 4, 2025 | $1.40 est $1.23 | $1.46B est $1.43B | +4.9% |
| Apr 24, 2025 | $1.37 est $1.19 | $1.46B est $1.43B | +12.6% |
| Feb 6, 2025 | $1.17 est $1.02 | $1.41B est $1.38B | −2.3% |
| Oct 28, 2024 | $1.03 est $0.94 | $1.35B est $1.38B | +7.0% |
| Aug 5, 2024 | $1.11 est $1.01 | $1.30B est $1.30B | −8.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Encompass Health is $156.08, +10.7% from the last close, from 9 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 9 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 2 | Mizuho Securities | $155 | +9.9% |
| Nov 2 | Leerink Partners | $177 | +25.5% |
| Oct 30 | UBS | $165 | +17.0% |
| Oct 30 | TD Cowen | $150 | +6.4% |
| Oct 30 | UBS | $165 | +17.0% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Encompass Health averaged −0.2% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.4% | 3 of 5 |
| Next 10 trading days | −1.3% | 3 of 5 |
| Next 15 trading days | −0.1% | 3 of 5 |
| Next 20 trading days | −0.2% | 3 of 5 |
| Next 30 trading days | −0.1% | 3 of 5 |
For scale, EHC’s typical 20-trading-day move in either direction is about 4.9%.
Encompass Health’s market cap is $13.83B, with a P/E ratio of 22.5 and revenue of $6.34B over the last twelve months.
Coverage of Encompass Health this week reads neutral: 0 positive, 3 neutral and 0 negative headlines.
Encompass Health’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LHLabcorp | Neutral | 8.5% above |
| GHGuardant Health | Accumulation | 16.4% below |
| SOLVSolventum | Neutral | 17.0% below |
| BTSGBrightSpring Health Services | Neutral | 11.0% above |
| ENSGEnsign | Neutral | 15.6% above |
| DVADaVita | Accumulation | 25.6% below |
A peer links to its own page where one exists.
Encompass Health’s market cap is $13.83B at the Nov 13, 2026 close of $140.99, with 98.12M shares outstanding. The shares trade on a P/E ratio of 22.5.
The consensus analyst 12-month price target for Encompass Health is $156.08, +10.7% from the last close. Of the 9 firms that rated the stock in the last 90 days, 9 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Encompass Health is overvalued: the Nov 13, 2026 close of $140.99 is 14.7% above Gekko Fair Value of $122.89. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Encompass Health is expected to report on Feb 4, 2027 (81 days away). Analysts expect earnings of $1.60 per share on revenue of $1.68B. Encompass Health beat the earnings estimate in 8 of its last 8 reports, moving 7.2% on average across the report.
Encompass Health’s 52-week high is $143.90 and its 52-week low is $92.77; it closed at $140.99 on Nov 13, 2026, +22.8% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 2 as mixed (gekkoindex and seasonality) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.